Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. DFTX
8. LLY
9. RGNX
10. LCO

Go back to Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1109.67 +11.10 (1.01%)
Previous Close $1098.57    52 Week High $88.16 
Open $1112.24    52 Week Low $67.88 
Day High $1119.45    P/E 256.87 
Day Low $1093.15    EPS $4.32 
Volume 937,931